Baylor University

“With great power comes great responsibility.”

Health care professionals around the world are reporting that the COVID-19 pandemic has prevented patients with systemic lupus erythematosus from receiving optimal care, resulting in increased risk for organ damage, according to a survey.

Use of continuous glucose monitoring among children and young adults with type 1 diabetes nearly doubled from 2017 to 2020 in the U.S. from 25% to 49% and was associated with lower HbA1c for users vs. non-users, according to registry data.

Between 2019 and 2021, organ offers and workload over time for liver and kidney allocation increased significantly, according to findings presented at the American Transplant Congress.

The SGLT2 inhibitor empagliflozin decreased risk for major renal outcomes in patients with heart failure with reduced ejection fraction but not preserved ejection fraction, according to an analysis of two large randomized controlled trials.

A wide array of potential etiologies can cause lung disease in rheumatoid arthritis patients, according to a presenter at the 2021 Congress of Clinical Rheumatology-East.

The FDA approved pembrolizumab for treatment of patients with high-risk, early-stage triple-negative breast cancer.

The FDA approved nivolumab as adjuvant treatment for certain patients with completely resected esophageal or gastroesophageal junction cancers, according to the agent’s manufacturer.

The addition of tesetaxel to reduced-dose capecitabine improved PFS among women with HER2-negative, hormone receptor-positive metastatic breast cancer, according to study results presented at the virtual San Antonio Breast Cancer Symposium.

Adjuvant nivolumab significantly prolonged DFS compared with placebo among patients with resected esophageal and gastroesophageal junction cancer, according to results of the CheckMate 577 trial presented during ESMO Virtual Congress 2020.